Efficacy and economic analysis of two treatment regimens using toltrazuril in lambs naturally infected with Eimeria spp. on pasture.

This study evaluated the efficacy and the economic viability of two anticoccidial treatment regimens tested in lambs naturally exposed to Eimeria spp. re-infections in a grazing system during a 140-day period. Twenty-four suckling lambs were distributed into three groups based on the individual count of oocysts per gram of feces (OPG) and body weight. Animals were treated with toltrazuril 5% (20 mg/kg) at 14- (GI) or 21-day (GII) intervals, and GIII was kept as untreated control. A cost-benefit analysis of each treatment regimen was calculated. Additionally, economic analysis was performed on four hypothetical scenarios, in which lambs could be having 10, 25, 50, or 85% decrease in their expected body weight gain due to clinical. Efficacy of toltrazuril against Eimeria spp. was 96.9-99.9% (GI) and 74.2-99.9% (GII). E. ovinoidalis was most frequently identified, but no clinical signs of coccidiosis were observed in lambs. There were no differences in weight gain among the groups. The cost of treatment per lamb was $13.09 (GI) and $7.83 (GII). The estimation model showed that the cost-benefit ratio favored treatment with toltrazuril when lambs fail to gain weight. In the studied flock, the break-even point for toltrazuril administered at 14-day intervals was reached with 85% decrease in mean weight gain. In conclusion, toltrazuril can be used at 14-day intervals to control Eimeria spp. (re)-infection in lambs raised on pasture. This treatment regimen was not economically feasible for subclinical coccidiosis; however, it may be feasible when used to prevent weight loss caused by clinical coccidiosis.

Measuring the costs of biosecurity on poultry farms: a case study in broiler production in Finland.

BACKGROUND: Farm-level biosecurity provides the foundation for biosecurity along the entire production chain. Many risk management practices are constantly in place, regardless of whether there is a disease outbreak or not. Nonetheless, the farm-level costs of preventive biosecurity have rarely been assessed. We examined the costs incurred by preventive biosecurity for Finnish poultry farms. METHODS: We used a semi-structured phone interview and obtained results from 17 broiler producers and from 5 hatching egg producers, corresponding to about 10% of all producers in Finland. RESULTS: Our results indicate that the average cost of biosecurity is some 3.55 eurocent per bird for broiler producers (0.10 eurocent per bird per rearing day) and 75.7 eurocent per bird for hatching egg producers (0.27 eurocent per bird per rearing day). For a batch of 75,000 broilers, the total cost would be €2,700. The total costs per bird are dependent on the annual number of birds: the higher the number of birds, the lower the cost per bird. This impact is primarily due to decreasing labour costs rather than direct monetary costs. Larger farms seem to utilise less labour per bird for biosecurity actions. There are also differences relating to the processor with which the producer is associated, as well as to the gender of the producer, with female producers investing more in biosecurity. Bird density was found to be positively related to the labour costs of biosecurity. This suggests that when the bird density is higher, greater labour resources need to be invested in their health and welfare and hence disease prevention. The use of coccidiostats as a preventive measure to control coccidiosis was found to have the largest cost variance between the producers, contributing to the direct costs. CONCLUSIONS: The redesign of cost-sharing in animal diseases is currently ongoing in the European Union. Before we can assert how the risk should be shared or resort to the 'polluter pays' principle, we need to understand how the costs are currently distributed. The ongoing study contributes towards understanding these issues. The next challenge is to link the costs of preventive biosecurity to the benefits thus acquired.

Influence of toltrazuril treatment on parasitological parameters and health performance of piglets in the field--an Austrian experience.

Porcine coccidiosis caused by Isospora suis is one of the leading causes of neonatal diarrhea in suckling piglets. Currently the only registered drug for metaphylaxis is toltrazuril. To evaluate the effect of treatment on piglets from 7 Austrian farms without and 8 Austrian farms with toltrazuril application we examined oocyst excretion (including determination of oocysts per gram of feces; OPG), diarrhea (fecal score FS 1-4 with 3 and 4 being diarrhea), and general health (health score HS 1-4 with 3 and 4 describing poor health). Both groups included farms with different levels of hygiene. Samples from 265 litters without treatment, comprising 1588 individual samples, and 1548 samples from 258 treated litters were taken twice (around the 14th and the 21st day of life, respectively), examined by autofluorescence and, if positive, by McMaster counting. In both groups animals had less diarrhea and lower health scores during the second sampling but the treated piglets were always significantly healthier and had less diarrhea. The percentage of weaned piglets was higher in treated animals although this was not significant (p=0.052). In the first round of sampling 17.8% of the individual samples from untreated piglets were positive for oocysts (with a maximum prevalence on the 12-15th day of life) while in the treated piglets only 0.4% shed oocysts p<0.001). At the second sampling only 2.1% of the untreated animals and none of treated piglets excreted I. suis (p=0.083). Positive animals shed up to 8 × 10(3)OPG. There was an increased risk for infected piglets to develop diarrhea (odds ratio, OR 4.73) and poor health (OR 5.05) in untreated piglets, and poor hygiene without disinfection was identified as a risk factor for poor health (OR 1.90), diarrhea (OR 1.42) and oocyst excretion (OR 1.73). The risk of poor health (OR 2.89) and diarrhea (OR 1.44) was also increased for piglets under poor hygienic conditions receiving toltrazuril, so both metaphylaxis of coccidiosis and good hygiene are necessary to effectively control neonatal diarrhea. The costs of treatment are considerably lower than the estimated financial production losses. Therefore, treatment is recommended for farms where clinical coccidiosis is diagnosed.

Toltrazuril and sulphonamide treatment against naturally Isospora suis infected suckling piglets: is there an actual profit?

A study was carried out to assess the efficacy and the economic profit of prophylactic treatment against Isopsora suis with toltrazuril or with a sulfamethazine/trimethoprim combination in piglets from an intensive pig farm. Thirty-one litters were included in study. Eight litters were treated once with toltrazuril (20 mg/kg b.w.) at 3 days of age (Toltra group); 8 litters were treated with 2 ml/animal of a [corrected] sulphonamide combination (sodium sulfamethazine 250 [DOSAGE ERROR CORRECTED] mg and trimethoprim 50 [DOSAGE ERROR CORRECTED] mg/kg b.w.) for 3 consecutive days starting at 3 days of age (Sulfa group), and 15 litters were untreated (control group). Counts of oocyst per gram on pooled feces sampled from each litter were carried out on Days 7, 14, 21 and 28 and diarrhea was registered daily from pooled samples. Piglets were weighed on Days 1, 7 and 28 and mean weight gain (WG) and daily weight gain (DWG) were evaluated. The economic profit of treatment was evaluated comparing the WG of piglets of each treatment group from the day of birth to Day 28. On Days 14, 21 and 28, toltrazuril showed a better efficacy in controlling fecal oocyst output, diarrhea and weight gain compared with sulphamidic treatment (P<0.001). The budgeting analysis showed a return of economic benefit of euro 0.915 per toltrazuril-treated piglets and an additional cost of euro 1.155 per sulphonamide-treated piglets.

Effects of toltrazuril on the growth of piglets in herds without clinical isosporosis.

Isospora suis is a widely prevalent and economically important parasite. The antiprotozoal compound, toltrazuril, was given as a single treatment to piglets without clinical signs in 10 herds. The daily weight gain (DWG) and mortality between the treatment date and weaning was compared on each herd in 10 treated and 10 control litters. The faeces of control litters were examined for oocyst excretion. In six herds, no oocysts were detected and treatment had no effect on DWG or mortality. In four pig herds, oocysts were detected and toltrazuril treatment significantly improved DWG by 25 g (P=0.003). Mortality rate was not affected. The partial economic benefit of toltrazuril treatment in positive herds was 0.20 euros per piglet. A single toltrazuril treatment of piglets in herds without clinical signs of isosporosis but with oocysts detected significantly improved DWG and was considered economically justified on each farm.

Financial analysis of various strategies for the control of Neospora caninum in dairy cattle in Switzerland.

The present study was conducted to estimate the direct losses due to Neospora caninum in Swiss dairy cattle and to assess the costs and benefits of different potential control strategies. A Monte Carlo simulation spreadsheet module was developed to estimate the direct costs caused by N. caninum, with and without control strategies, and to estimate the costs of these control strategies in a financial analysis. The control strategies considered were "testing and culling of seropositive female cattle", "discontinued breeding with offspring from seropositive cows", "chemotherapeutical treatment of female offspring" and "vaccination of all female cattle". Each parameter in the module that was considered to be uncertain, was described using probability distributions. The simulations were run with 20,000 iterations over a time period of 25 years. The median annual losses due to N. caninum in the Swiss dairy cow population were estimated to be euro 9.7 million euros. All control strategies that required yearly serological testing of all cattle in the population produced high costs and thus were not financially profitable. Among the other control strategies, two showed benefit-cost ratios (BCR) >1 and positive net present values (NPV): "Discontinued breeding with offspring from seropositive cows" (BCR=1.29, NPV=25 million euros ) and "chemotherapeutical treatment of all female offspring" (BCR=2.95, NPV=59 million euros). In economic terms, the best control strategy currently available would therefore be "discontinued breeding with offspring from seropositive cows".

Economic benefits of prophylaxis with diclazuril against subclinical coccidiosis in lambs reared indoors.

One hundred and twenty weaned male lambs, naturally infected with Eimeria species, were used to assess the economic benefits of the prophylactic administration of diclazuril. They were randomly divided into four groups of 30 lambs on the basis of their bodyweight and output of oocysts. The groups were either left untreated (group 1), treated orally with a simple dose of diclazuril at 1 mg/kg (group 2), with two doses two weeks apart (group 3), or with sulphadimethoxine at 50 mg/kg for five consecutive days (group 4). No clinical signs of coccidiosis were observed in any of the groups. The output of oocysts was significantly reduced on day 7 after treatment in group 2, on days 7, 14 and 28 in group 3 and on days 7 and 14 in group 4. No significant differences were found between the treated and untreated groups for bodyweight, carcase weight and carcase classification. The mean fattening period was shorter for the treated lambs (52 and 55 days) than for the untreated controls (60 days). The average growth rate of the lambs treated twice with diclazuril and with sulphadimethoxine was improved and the feed conversion rates of the lambs treated once or twice with diclazuril were 7 per cent and 16 per cent better than that of the untreated lambs.